ABECMA (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
This website is best viewed using the horizontal display on your tablet device.
This website is best viewed using the vertical display on your mobile device.
Bristol Myers Squibb’s Cell Therapy 360® program supports patients and caregivers throughout their treatment journey, from enrollment through the initial post-infusion monitoring period, with referral resources, patient support navigators, logistical support*, and financial support*.
*Eligibility requirements may apply.
Patients may enroll in support programs offered through Cell Therapy 360 after a certified CAR T treatment center determines that ABECMA® is the right treatment for them.
The services and support programs offered through Cell Therapy 360 are available only to people who are receiving a CAR T cell therapy from Bristol Myers Squibb, such as ABECMA. Certain restrictions and eligibility requirements apply.
CAR=chimeric antigen receptor.